Procainamide (hydrochloride)
CAT:
804-HY-A0084-02
Size:
100 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Procainamide (hydrochloride)
- CAS Number: 614-39-1
- UNSPSC Description: Procainamide hydrochloride (Procaine amide hydrochloride) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide hydrochloride induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide hydrochloride relaxes airway smooth muscle by activating potassium channels. Procainamide hydrochloride can be used in cancer and arrhythmia research[1][2][3][4][5][6].
- Target Antigen: DNA Methyltransferase; Potassium Channel
- Type: Reference compound
- Related Pathways: Epigenetics;Membrane Transporter/Ion Channel
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/Procainamide-hydrochloride.html
- Purity: 99.89
- Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : ≥ 50 mg/mL
- Smiles: O=C(NCCN(CC)CC)C1=CC=C(N)C=C1.[H]Cl
- Molecular Weight: 271.79
- References & Citations: [1]Lee BH, et al. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem. 2005;280(49):40749-40756.|[2]Pritchard B, et al. Procainamide. [Updated 2021 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.|[3]Gardner I, et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo[J]. Chemical research in toxicology, 2005, 18(9): 1384-1394.|[4]Nakahara T, et al. Involvement of K+ channel in procainamide-induced relaxation of bovine tracheal smooth muscle[J]. European journal of pharmacology, 2000, 402(1-2): 143-149.|[5]Morissette G, et al. Massive cell vacuolization induced by organic amines such as procainamide[J]. Journal of Pharmacology and Experimental Therapeutics, 2004, 310(1): 395-406.|[6]Segura-Pacheco B, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy[J]. Clinical Cancer Research, 2003, 9(5): 1596-1603.Clin Chem. 2019 Dec;65(12):1522-1531. |Patent. US20180263995A1.|Environ Pollut. 2023 May 31;121931.|Free Radic Biol Med. 2024 Jun 1:S0891-5849(24)00506-9.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
- Clinical Information: Launched